Merck immunotherapy drug shows promise against lymphoma: study

December 6, 2014 6:06 PM

14 0

(Reuters) - Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting.

In the ongoing study of 29 patients, 66 percent had a meaningful response to the drug, Keytruda, after 24 weeks of treatment, including six patients (21 percent) who achieved complete remission.

Read more

To category page